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Abstract Low density lipoprotein (LDL) metabolism was in- 
vestigated using a pulse injection of ‘251-labeled LDL in 20 
subjects who did not have familial hypercholesterolemia (FH) 
(plasma cholesterol 160-297 mg/dl) and in 9 subjects who did 
have heterozygous FH (plasma cholesterol 273-50 1 mg/dl). 
Subjects were also injected with ’311-labeled LDL chemically 
modified with cyclohexanedione. This technique permitted a 
calculation of the amount of apoLDL removed via receptor- 
mediated and receptor-independent pathways. In subjects 
without FH, 40% (range 25-49%) of LDL was cleared via 
receptor-mediated pathways and in subjects with FH this fig- 
ure was 22% (range 3-33%). In nonfamilial hypercholester- 
olemia there was clear evidence of defective removal of LDL 
via receptor-independent pathways in association with some 
overproduction of apoLDL. In heterozygous FH there was 
evidence of defective removal of LDL via receptor-mediated 
pathways, while some subjects also showed evidence of over- 
production of ap0LDL.I It is suggested that LDL catabolism 
via receptor-independent pathways plays a major role in reg- 
ulating plasma cholesterol levels in the normal to moderately 
elevated range.-Simons, L. A., S. Balasubramaniam, and 
J. Holland. Low density lipoprotein metabolism in the normal 
to moderately elevated range of plasma cholesterol: compar- 
isons with familial hypercholesterolemia. J .  Lipid Res. 1983. 
24: 192-199. 
Supplementary key words nonfamilial hypercholesterolemia cy- 
clohexanedione modification * receptor-mediated pathways * receptor- 
independent pathways 
Low density lipoprotein (LDL) metabolism has been 
extensively investigated in vivo in patients who have 
monogenic familial hypercholesterolemia (FH), both in 
the heterozygous (1-4) and homozygous forms (2, 5) .  
Although FH is closely linked with premature athero- 
sclerosis and coronary heart disease, the gene frequency 
for FH in the general population is relatively low (6). 
Hence, most patients with coronary heart disease and 
moderate hypercholesterolemia have elevated LDL 
cholesterol levels due to an alternative, ill-defined lipid 
transport disorder, which may be secondary to dietary 
and polygenic factors (7). LDL metabolism in these pa- 
tients has been investigated only to a very limited extent 
and requires further clarification. 
Many cell types throughout the body contain specific 
receptors that facilitate LDL uptake and degradation, 
supplying cholesterol to body cells while suppressing 
their endogenous cholesterol synthesis (8, 9). Receptor 
recognition in these cells depends on the presence of 
functionally significant arginyl residues in the LDL 
apoprotein. This functional group may be “blocked” 
by various chemical modifications that ideally produce 
no other significant change in the LDL molecule (10). 
The administration of modified LDL has enabled the 
assessment of receptor-mediated and receptor-indepen- 
dent LDL catabolism in intact man (4, 11). We have 
used these techniques to study LDL metabolism in sub- 
jects not manifesting FH, who were drawn from the 
normal to moderately elevated range of LDL concen- 
tration. The results indicate that subjects with moderate 
hypercholesterolemia have defective catabolism of 
apoLDL via receptor-independent pathways associated 
with some overproduction of apoLDL. 
METHODS 
Subjects 
The studies were performed in 29 subjects whose 
clinical data are recorded in Table 1. The diagnosis of 
FH in the heterozygous form was an arbitrary one based 
on an LDL cholesterol level in excess of 220 mg/dl, 
plus the presence of at least two of the following three 
characteristics: xanthomatous disease, similarly affected 
first degree relatives, and premature coronary heart 
disease under the age of 35 years. Subjects without FH 
Abbreviations: LDL, low density lipoprotein; VLDL, very low den- 
sity lipoprotein; apoLDL, apoprotein of LDL; FH, familial hypercho- 
lesterolemia; CHD, 1,Zcyclohexanedione; FCR, fractional catabolic 
rate of apoLDL; ACR, absolute catabolic rate of apoLDL. 
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TABLE 1. Clinical data 
Plasma Cholesterol 
Plasma 
Subject Age Sex Weight Total VLDL LDL HDL Triglycerides 
Y' t 
Subjects without familial hypercholesterolemiaa 
L.S. 
F.G. 
V.H. 
A.M. 
F.C. 
I.C. 
A.N. 
B.S. 
M.G. 
M.T. 
R.C. 
AS. 
B.U. 
F.K. 
A.G. 
E.G. 
W.S. 
N.T. 
P.S. 
C.P. 
38 
56 
53 
55 
65 
51 
54 
45 
31 
55 
65 
50 
45 
45 
74 
74 
35 
53 
30 
18 
M 
M 
F 
M 
M 
F 
F 
M 
F 
F 
F 
M 
F 
F 
M 
F 
M 
M 
M 
M 
93 
67 
65 
82 
72 
58 
51 
119 
85 
82 
59 
86 
53 
51 
53 
47 
77 
69 
75 
73 
Mean f S.D. #1 4 5 +  16 73 + 20 
Mean f S.D. #2 58 + 9 67 + 17 
Subjects with familial hypercholesterolemia 
J.R. 
L.C. 
T.B. 
M.E. 
M.H. 
D.I. 
R.W. 
J.C. 
S.D. 
49 
63 
47 
62 
42 
34 
57 
42 
70 
69 
51 
62 
70 
59 
80 
66 
60 
73 
Mean * S.D. 5 2 +  12 66 * 9 
179 
173 
260 
243 
234 
240 
27 1 
195 
210 
265 
297 
297 
209 
160 
181 
247 
191 
223 
190 
175 
197 + 26 
269 * 23' 
297 
453 
273 
50 1 
327 
308 
447 
485 
339 
381 + 89'8' 
6 
10 
9 
5 
19 
2 
3 
21 
12 
14 
27 
27 
28 
9 
19 
10 
4 
10 
3 
9 
12 f 8 
1 4 +  11 
mgldl  
132 
112 
189 
187 
173 
171 
192 
144 
160 
199 
220 
236 
136 
102 
116 
183 
139 
164 
133 
120 
139 + 24 
201 + 216 
6 257 
35 382 
3 223 
15 443 
40 24 1 
14 260 
7 395 
12 430 
58 250 
21 f 19 320 ? 906.' 
41 
51 
62 
51 
42 
67 
76 
30 
38 
52 
50 
34 
45 
49 
46 
54 
48 
49 
54 
46 
47 + 9 
5 4 +  14 
34 
36 
47 
43 
46 
34 
45 
43 
31 
40 + 6' 
mgldl  
171 
148 
187 
125 
188 
58 
104 
285 
234 
210 
293 
287 
252 
162 
186 
173 
156 
168 
154 
139 
177 f 59 
197 k 79 
157 
405 
134 
245 
282 
212 
262 
198 
256 
239 & 7g6 
The  first 12 subjects were nonvegetarians and the last 8 were vegetarians. These 20 subjects were arbitrarily classified into those with LDL 
cholesterol < 180 mg/dl (Mean #1, n = 13) and those with LDL cholesterol 2 180 mg/dl (Mean #2, n = 7). ' Significantly different from Mean #1 (P < 0.05 or less). 
Significantly different from Mean #2 (P < 0.02 or less). 
exhibited a range of LDL cholesterol levels, but had 
none of the additional characteristics used to define FH. 
None of the 29 subjects exhibited disease affecting 
renal, hepatic, or endocrine systems. Some of the hy- 
percholesterolemic subjects had previously used drugs 
affecting lipid metabolism, but not in the 2 to 3 months 
prior to study. 
Studies were conducted on an outpatient basis and 
subjects were instructed to continue their existing diets. 
Vegetarian subjects had been consuming a lacto-ovo- 
vegetarian diet, most of the hypercholesterolemic sub- 
jects had been consuming a diet restricted in cholesterol 
and saturated fat, while the remaining subjects were 
consuming a typical Australian ad lib diet. Nutrient in- 
take was assessed by 24-hr recall to confirm the dietary 
status (1 2). Research protocols were approved by Ethics 
and Research Committees at St. Vincent's Hospital and 
the University of New South Wales, and each subject 
gave informed consent prior to participation. 
Preparation and chemical modification of 
labeled LDL 
Sixty ml of blood was collected in EDTA (0.1 % w/ 
v) from each subject. LDL (1.019 < d < 1.055 g/ml) 
was isolated by preparative ultracentrifugation and pu- 
rified by re-centrifugation at d 1.055 g/ml. The LDL 
was dialyzed against 0.15 M NaCI-0.01% EDTA, pH 
7.4 (4"C), and then divided into two aliquots that were 
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labeled with Na l z 5 l  or  Na I 3 ’ l  (Radiochemical Centre, 
Amersham) using a modification of the iodine mono- 
chloride method (1). Labeled lipoproteins were then 
dialyzed exhaustively against the above-mentioned 
buffer. The  efficiency of iodination was 15-40%, the 
degree of lipid labeling was 2-6% (chloroform-meth- 
anol 2:l extraction), and the amount of label precipi- 
table by trichloracetic acid was >97%. ‘“1-labeled LDL 
(3 mg) was modified with 1,2-~yclohexanedione (CHD) 
as previously described (1 0). ‘251-labeled LDL was sim- 
ilarly treated at 35°C for 2 hr  in sodium borate buffer 
(0.2 M ,  pH 8.1) but CHD was not added. The  samples 
were then exhaustively dialyzed against 0.15 M NaC1- 
0.0 1 % EDTA, pH 7.4. A small aliquot was checked for 
radiochemical purity and CHD modification using aga- 
rose gel electrophoresis and autoradiography. Each la- 
beled LDL migrated as a single band, while CHD-mod- 
ified LDL migrated with substantially increased anodic 
mobility, as previously demonstrated (4). Each sample 
was then sterilized by membrane filtration (0.22 hm fil- 
ter, Millipore Corp.), a small aliquot was reserved for 
dosimetry, and approximately 25 FCi of each tracer 
(0.5-1.0 mg protein) was made ready for re-injection 
into the donor. 
Lipoprotein turnover studies 
For 3 days prior to re-injection and for the duration 
of the investigation each subject consumed 180 mg/day 
of K l  to prevent thyroidal uptake of radioiodide. Five 
days after initial sampling, the donor was re-injected 
with each label sequentially through a running intra- 
venous line kept open with 0.9% saline. Blood samples 
were then collected at 5 min (for estimation of plasma 
volume by isotope dilution) and thereafter daily for 12- 
14 days. The  plasma decay curve for each tracer could 
be resolved into two exponentials and kinetic parame- 
ters were calculated according to Matthews (1 3), as de- 
scribed previously (5). The  parameters derived from 
‘251-labeled LDL related to overall LDI, metabolism, 
and those derived from ’311-labeled LDL were assumed 
to relate to LDL metabolism via receptor-independent 
pathways. Receptor-mediated metabolism was calcu- 
lated as the difference between total and receptor-in- 
dependent turnover, as demonstrated by Shepherd et 
al. (4). 
Other measurements and statistical methods 
The  concentration of apoLDL for the duration of a 
turnover study was obtained as follows. T w o  plasma 
pools representing the first and second halves of each 
study period were created by drawing a small aliquot 
from each daily sample; total radioactivities in these 
samples were assessed; LDL (1 .O 19 < d < 1.055 g/ml) 
was isolated in the preparative ultracentrifuge and its 
specific radioactivity was measured by counting and by 
Lowry assay using a standard of bovine serum albumin 
(14); apoLDL concentration was then calculated from 
specific radioactivity and total radioactivity in plasma. 
Standard diagnostic separations of lipoprotein classes 
were performed according to previously published 
methods (1 5). Plasma cholesterol and triglyceride con- 
centrations were measured on the Technicon Autoan- 
alyzer (Methods N-24a and N-78, respectively). Data 
was analyzed using the Statistical Package for the Social 
Sciences (1 6). The means of various samples were com- 
pared using t-test for independent samples (two-tailed 
distribution), while correlation analysis examined only 
the linear Pearson correlation. 
RESULTS 
Subjects without familial hypercholesterolemia 
This was a diverse group of subjects with plasma cho- 
lesterol concentrations extending from 160 to 297 mg/ 
dl, the lower cholesterol levels generally belonging to 
the vegetarian subjects (Table 1). T o  overcome some 
of this heterogeneity, these subjects were arbitrarily 
subgrouped into those with LDL cholesterol levels 
above and below 180 mg/dl (“hypercholesterolemics”, 
n = 13 and “normals”, n = 7). Mean (fS.D.) plasma 
cholesterol levels were respectively 269 k 23 and 197 
f 26 mg/dl (P  < 0.001), while LDL cholesterol levels 
were respectively 201 5 21 and 139 ? 24 mg/dl 
(P  < 0.001). Plasma triglyceride and VLDL cholesterol 
concentrations did not differ significantly between the 
two subgroups (Table 1). 
The  kinetic parameters of LDL metabolism are sum- 
marized in Table 2. The  rate of clearance of LDL was 
38-42% slower in the presence of CHD-modification, 
indicating that a minimum 40% of LDL was cleared in 
vivo via specific receptors. 
The  relationships between apoLDL concentration 
and overall LDL catabolism are presented in Fig. 1. 
The concentration of apoLDL was negatively correlated 
with its fractional catabolic rate (FCR) ( r  = -0.49, 
P < 0.02) and positively correlated with its absolute cat- 
abolic rate (ACR) (r = 0.50, P < 0.02). There was a sig- 
nificantly lower FCR in hypercholesterolemic subjects 
versus normals (0.264 f 0.023/day versus 0.308 
k 0.040, P < 0.02). ACR tended to be higher in hy- 
percholesterolemic subjects compared to normals, but 
this difference was not statistically significant. 
The  relationships between apoLDL concentration 
and catabolism of LDL via receptor-mediated and re- 
ceptor-independent pathways are presented in Fig. 2. 
The concentration of apoLDL was negatively correlated 
with FCR via receptor-independent pathways ( r  
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TABLE 2. Kinetic parameters of LDL metabolism 
FCR ACR 
Plasma Plasma 
Subject Volume apoLDL Total RI RM Total RI RM 
ml m g l d l  da?-' mglkg per day  
Subjects without familial hypercholesterolemia 
L.S. 
F.G. 
V.H. 
A.M. 
F.C.O 
I.C. 
A.N. 
B.S." 
M.G. 
M.T. 
R.C. 
A.S. 
B.U. 
F.K. 
A.G. 
E.G. 
W.S. 
N.T. 
P.S. 
C.P. 
4049 70 
2885 79 
2454 124 
3888 101 
2729 97 
2722 76 
2160 107 
3153 114 
2589 111 
2874 131 
1799 132 
3045 123 
2709 83 
2350 59 
2282 91 
209 1 104 
3920 100 
2497 89 
3452 59 
2582 60 
0.295 
0.279 
0.263 
0.260 
0.291 
0.272 
0.224 
0.337 
0.265 
0.262 
0.293 
0.279 
0.293 
0.401 
0.356 
0.268 
0.288 
0.294 
0.306 
0.328 
0.206 
0.151 
0.135 
0.144 
0.140 
0.141 
0.163 
0.143 
0.169 
0.186 
0.185 
0.217 
0.222 
0.155 
0.177 
0.221 
0.205 
0.224 
0.089 
0.128 
0.128 
0.116 
0.132 
0.083 
0.102 
0.119 
0.124 
0.093 
0.108 
0.184 
0.134 
0.113 
0.111 
0.073 
0.101 
0.104 
9.0 
9.5 
12.3 
12.5 
10.7 
9.7 
10.2 
10.2 
9.0 
12.0 
11.8 
12.2 
12.4 
10.9 
14.0 
12.4 
14.7 
9.5 
8.3 
7.0 
6.3 
5.1 
6.3 
6.9 
5.0 
6.4 
5.5 
6.6 
6.8 
8.1 
7.9 
5.9 
8.7 
7.2 
9.0 
7.2 
5.6 
4.8 
2.7 
4.4 
6.0 
5.6 
4.7 
3.8 
3.5 
5.5 
5.0 
4.1 
4.6 
5.0 
5.3 
5.2 
5.7 
2.4 
2.7 
2.2 
Mean f S.D. # I b  84 f 20 0.308 f 0.040 0.192 f 0.032 0.115 f 0.031 10.4k 2.3 6 . 5 k  1.6 3.9 f 1.3 
Mean f S.D. #2 117+14c  0.264f0.023C 0.153f0.O2Oc 0.111 fO.018 11.9fO.9 6 . 9 f 0 . 7  5 . 0 f 0 . 9  
Subjects with familial hypercholesterolemia 
J.R. 
L.C. 
T.B. 
M.E. 
M.H. 
D.1. 
R.W. 
J.C. 
S.D. 
2942 
2032 
2344 
2580 
2027 
2843 
2038 
1942 
2377 
143 
238 
157 
208 
116 
164 
207 
180 
154 
0.208 
0.172 
0.277 
0.162 
0.257 
0.234 
0.189 
0.178 
0.183 
0.156 
0.160 
0.186 
0.134 
0.172 
0.178 
0.142 
0.141 
0.178 
0.052 
0.012 
0.091 
0.028 
0.085 
0.056 
0.047 
0.037 
0.005 
12.7 
16.3 
16.4 
12.4 
10.2 
13.6 
12.1 
10.4 
9.2 
9.5 
15.2 
11.0 
10.3 
6.9 
10.4 
9.1 
8.2 
9.0 
3.2 
1.1 
5.4 
2.2 
3.4 
3.3 
3.0 
2.2 
0.3 
Mean f S.D. 1745 38C*d 0.207 f 0.040C,d 0.161 f 0.019c 0.046 f 0.029'~~ 12.6 f 2.5' 9.9 f 2.3'jd 2.7 f 1.5d 
' These subjects did not receive CHD-modified LDL. 
See footnote a Table 1. 
' Significantly different from Mean # I  (P < 0.05 or less). 
Significantly different from Mean #2 (P < 0.01 or less). 
= -0.58, P < 0.01), but showed no significant relation- 
ship with FCR via receptor-mediated pathways. These 
findings were supported in hypercholesterolemic versus 
normal subjects by a significantly lower FCR via recep- 
tor-independent pathways (0.153 -t 0.020/day versus 
0.192 & 0.032, P < 0.01), and by similar FCR for each 
subgroup via receptor-mediated pathways. 
ApoLDL concentration was positively correlated 
with ACR via receptor-mediated ( r  = 0.50, P < 0.02) 
and receptor-independent pathways ( r  = 0.39), al- 
though the latter failed to reach statistical significance 
(P = 0.053). Hypercholesterolemic compared with nor- 
mal subjects tended to have higher ACR via receptor- 
mediated pathways. 
Nonvegetarian subjects consumed more cholesterol 
than vegetarians (345 f 252 mg/day versus 119 -t 57, 
P < 0.05). Mean FCR of apoLDL in nonvegetarians was 
significantly lower than in vegetarians (0.277 & 0.029/ 
day versus 0.317 & 0.043, P < 0.02). This decrease in 
FCR of apoLDL was due to a decrease in FCR via re- 
ceptor-independent pathways (0.158 & 0.023/day ver- 
sus 0.201 2 0.026, P < 0.002). 
Subjects with familial hypercholesterolemia 
Subjects with FH were of similar age and body mass 
index to subjects without FH. They had significantly 
higher total and LDL cholesterol levels (Table I). The 
Simons, Balasubramaniam, and Holland LDL metabolism in moderate hypercholesterolemia 195 
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average nutrient intakes of both groups were broadly 
similar (188 -t 72 mg/day of cholesterol in FH versus 
260 k 228 in non-FH; 38 8% of energy from fat in 
FH versus 34 f 11 in non-FH; 30 k 6 Kcal/kg per day 
in FH versus 30 5 8 in non-FH). 
The kinetic parameters of LDL metabolism in sub- 
jects with FH are presented in Table 2. The FCR of 
apoLDL was significantly lower in FH compared with 
normals (0.207 k 0.040/day versus 0.308 f 0.040, 
P < 0.001), due to a removal defect principally confined 
to receptor-mediated pathways (see Fig. 3.) Mean ACR 
in FH was slightly higher than in normals (12.6 & 2.5 
mg/kg per day versus 10.4 f 2.3, P < 0.05), but did 
not differ significantly from that in hypercholesterol- 
emia not due to FH. ACR in FH via receptor-indepen- 
dent pathways was significantly higher and ACR in FH 
via receptor-mediated pathways tended to be lower than 
in either normal subjects or in those with hypercholes- 
terolemia not due to FH (see Table 2 and Fig. 4). 
In subjects with FH, apoLDL concentration was neg- 
atively correlated with total FCR (r = -0.69, P < 0.02) 
and with FCR via receptor-mediated pathways (r 
= -0.59, P < 0.05). AopLDL concentration was not 
significantly correlated with ACR. 
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Fig. 2. The relationships between receptor-mediated and receptor-independent catabolism and apoLDL concenrration in subjects without FH. 
Receptor-independent catabolism was derived from '"'I-labeled LDL metabolism and receptor-mediated catabolism from the difference between 
'*'I-labekd LDL and 's'l-labeIed LDL metabolism. 
DISCUSSION and its metabolism. However, the extremes of diet ex- 
perienced in the present study were accepted in the 
hope of highlighting any subtle metabolic relationship 
that might have remained concealed in subjects con- 
suming more homogeneous diets. Although the data 
have been analyzed for a continuum of LDL protein 
concentration from the normal to moderately elevated 
In many respects the subjects without FH represent 
a grouping of diverse metabolic variables, including 
diet, physical activity, genetic and other environmental 
factors. This was likely to complicate interpretation of 
any observed relationships between LDL concentration 
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Fig. 3. Parameters of fractional LDL catabolism in subjects with FH 
and without FH (‘non FH’). Horizontal bars represent mean values. 
range, it has also proved useful to examine the data in 
an independent manner by subdividing the subjects 
above and below an arbitrary LDL cholesterol concen- 
tration. Fortuitously, the hypercholesterolemic and nor- 
mal subgroups have similar levels of plasma triglycerides 
and other lipoprotein classes and this has removed the 
potentially confounding influence of variations in the 
transport of triglyceride-rich lipoproteins. 
Our findings clearly suggest that in subjects without 
FH, m0derat.e hypercholesterolemia is due to a defect 
in LDL removal mechanisms. Somewhat weaker evi- 
dence has been obtained to suggest that these subjects 
may also have above-normal production rates of apoLDL 
(equivalent to ACR in the metabolic steady state). In a 
recent investigation, where diet was the same in all sub- 
jects, Kesaniemi and Grundy (1 7) found that moderate 
hypercholesterolemia was clearly associated with over- 
production of apoLDL, yet these patients failed to man- 
ifest a removal defect. This contrast with our own re- 
sults is possibly due to differences in case selection and 
in diet, and suggests that moderate hypercholesterol- 
emia not due to FH may be associated with a combi- 
nation of defective catabolism and overproduction of 
apoLDL, or with overproduction alone. 
Our results confirm the previous observation that a 
chemical modification of functional arginyl residues in 
apoLDL leads to slower clearance of LDL from plasma 
in vivo (4). Two assumptions have been made in inter- 
preting the results: i) modified LDL is removed only via 
receptor-independent pathways, and ii) modified LDL 
is catabolized at the same rate as native LDL via recep- 
tor-independent pathways. It is possible that some CHD- 
modified LDL is still removed via specific receptors, but 
this is very difficult to evaluate. Hence, the proportion 
of LDL removed via receptor-mediated pathways must 
be regarded as a minimum estimate. Recent data from 
Slater, Packard, and Shepherd (1 8) further support the 
use of CHD-modified LDL as a suitable marker for the 
study of receptor-independent catabolism in vivo. Based 
on the above-mentioned assumptions, our calculations 
show that in normal subjects (mean plasma cholesterol 
197 mg/dl) a minimum of 37% of LDL is removed via 
receptor-mediated pathways. This is in good agreement 
with a figure of 33% observed by Shepherd et al. (4). 
In subjects with heterozygous FH (mean plasma cho- 
lesterol 38 1 mg/dl), LDL removal via receptor-me- 
diated pathways was reduced to a minimum mean value 
of 22%. In all of our subjects examined, the major por- 
tion of LDL is removed from plasma via receptor-in- 
dependent pathways. 
The use of modified LDL in the current investigation 
has provided new information on LDL metabolism in 
subjects with nonfamilial hypercholesterolemia. In sub- 
jects without FH, LDL levels appear to be regulated in 
part by the FCR of apoLDL (Fig. 1). This regulation, 
in turn, appears to be related to the amount of apoLDL 
removed via receptor-independent pathways (Fig. 2). 
There is little relationship between receptor-mediated 
removal of LDL and its concentration in these subjects, 
which is in contrast to the situation in FH. The present 
observations suggest, for the first time, that a removal 
defect for LDL via receptor-independent pathways is 
an important contributing factor in nonfamilial hyper- 
cholesterolemia, in association with some overproduc- 
tion of apoLDL. Although some hypercholesterolemic 
patients may manifest overproduction of apoLDL as the 
sole metabolic lesion (1 7), subjects in the present study 
manifest clearer evidence of a removal defect. We have 
not noted a pronounced overproduction of apoLDL 
and it is suggested that the removal defect via receptor- 
independent pathways could be the dominant lesion in 
these cases. 
Although much is known about the properties of 
LDL receptors, the mechanisms involved in receptor- 
independent pathways are unclear. The reticuloendo- 
thelial system may well play an important role (1 9). Oui- 
findings in vegetarians do suggest that a diet high in 
cholesterol is associated with a significant reduction in 
TOTAL RECEPT - ltND 
FH NON FH NOR 
FH FH 
RECEPT 
M E D  
.... 
L 
FH NON 
FH 
Fig. 4. Parameters of absolute LDL catabolism in subjects with FH 
and without FH (‘non FH’). Horizontal bars represent mean values. 
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LDL removal via the receptor-independent pathways. 
However, the design of the present study precludes any 
precise measurement of the relationship between diet 
and LDL metabolism. Other studies have shown that 
vegetarianism may influence both LDL production and 
removal (20), and that polyunsaturated fats may en- 
hance LDL catabolism (21). 
Earlier studies and our present results here confirm 
that elevated LDL levels in FH are associated with a 
reduced FCR of apoLDL (1-5). There is, however, con- 
troversy as to whether heterozygous subjects for FH 
overproduce LDL or not. In the present study only two 
subjects out of nine had undisputed evidence of over- 
production of apoLDL (Fig. 4). These observations sug- 
gest that defective removal and overproduction of 
apoLDL can be independent phenomena, as in the non- 
familial subjects.U 
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